Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Pharmacokinetics of hard micronized progesterone capsules via vaginal or oral route compared with soft micronized capsules in healthy postmenopausal women: a randomized open-label clinical study

Tytuł:
Pharmacokinetics of hard micronized progesterone capsules via vaginal or oral route compared with soft micronized capsules in healthy postmenopausal women: a randomized open-label clinical study
Autorzy:
Wang H
Liu M
Fu Q
Deng C
Temat:
micronized progesterone hard capsule
micronized progesterone soft capsule
pharmacokinetics
vaginal administration
oral administration
Therapeutics. Pharmacology
RM1-950
Źródło:
Drug Design, Development and Therapy, Vol Volume 13, Pp 2475-2482 (2019)
Wydawca:
Dove Medical Press, 2019.
Rok publikacji:
2019
Kolekcja:
LCC:Therapeutics. Pharmacology
Typ dokumentu:
article
Opis pliku:
electronic resource
Język:
English
ISSN:
1177-8881
Relacje:
https://www.dovepress.com/pharmacokinetics-of-hard-micronized-progesterone-capsules-via-vaginal--peer-reviewed-article-DDDT; https://doaj.org/toc/1177-8881
Dostęp URL:
https://doaj.org/article/fe64d74297f34206870941a9bad74750  Link otwiera się w nowym oknie
Numer akcesji:
edsdoj.fe64d74297f34206870941a9bad74750
Czasopismo naukowe
Hanbi Wang,1 Meizhi Liu,1 Qiang Fu,2 Chengyan Deng11Reproductive Center, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, People’s Republic of China; 2Department of Pharmacy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, People’s Republic of ChinaPurpose: This study aimed to evaluate the pharmacokinetics of hard micronized progesterone capsules (Yimaxin) via the vaginal or oral route compared with soft micronized progesterone capsules (Utrogestan) in a Chinese population.Methods: A prospective single-center randomized open-label trial was conducted in 16 healthy postmenopausal women. They were randomized into two groups to receive four phases of treatment: vaginal Yimaxin, vaginal Utrogestan, oral Yimaxin, or oral Utrogestan, with different sequences.Results: By the vaginal route, steady-state maximum concentration (Cmax) of Yimaxin and Utrogestan was 29.13±8.09 and 12.30±1.60 mg/L, time to Cmax 9.72±10.50 and 11.03±9.62 hours, central compartment volume of distribution 4.26±1.86 and 10.40±2.32 L, clearance rate 0.18±0.05 and 0.38±0.10 L/h, and AUC 261.42±74.36 and 116.83±19.72 h·ng/mL, respectively. By the oral route, Cmax of Yimaxin and Utrogestan was 62.97±40.59 and 169.53±130.24 mg/L, time to Cmax was 2.88±1.35 and 2.06±1.55 hours, central compartment volume of distribution 132.16±52.13 and 85.08±55.07 L, clearance rate 3.43±1.07 and 2.50±1.04 L/h, and AUC 274.86±160.28 and 472.00±250.54 h·ng/mL, respectively. By the vaginal route, Cmax, minimum concentration, AUC0–72, and AUC of Yimaxin were higher than Utrogestan, while by the oral route the Cmax, AUC0–72, and AUC of Utrogestan were higher than Yimaxin.Conclusion: Pharmacokinetic parameters were different between Yimaxin and Utrogestan on vaginal and oral administration. By the oral route, the metabolism and absorption of Utrogestan was superior to Yimaxin, while by the vaginal route Yimaxin was superior.Keywords: micronized progesterone hard capsule, micronized progesterone soft capsule, pharmacokinetics, vaginal administration, oral administration

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies